Search form
Search
contact us
Navigation
home
boards
job center
job ratings
cp wire
device news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» Keytruda
Keytruda
GSK stops Keytruda combo trials after ICOS drug falls short
GSK stops Keytruda combo trials after ICOS drug falls short
Fierce Biotech
GSK
feladilimab
Keytruda
clinical trials
ICOS
Flag link:
Merck's Keytruda, on the heels of a first-line kidney cancer win, targets earlier, post-surgery use
Merck's Keytruda, on the heels of a first-line kidney cancer win, targets earlier, post-surgery use
Fierce Pharma
Merck
Keytruda
renal cell carcinoma
kidney cancer
clinical trials
Flag link:
FDA busts Merck's Keytruda in triple-negative breast cancer with a CRL — not unexpected given its disastrous adcomm
FDA busts Merck's Keytruda in triple-negative breast cancer with a CRL — not unexpected given its disastrous adcomm
Endpoints
Merck
FDA
Keytruda
triple negative breast cancer
Flag link:
FDA busts Merck's Keytruda in triple-negative breast cancer with a CRL — not unexpected given its disastrous adcomm
FDA busts Merck's Keytruda in triple-negative breast cancer with a CRL — not unexpected given its disastrous adcomm
Endpoints
Merck
FDA
Keytruda
triple negative breast cancer
Flag link:
Merck Scores Latest Label Expansion for Keytruda in Esophageal Carcinomas
Merck Scores Latest Label Expansion for Keytruda in Esophageal Carcinomas
BioSpace
Merck
Keytruda
esophageal cancer
FDA
Flag link:
Merck breathes a sigh of relief as Keytruda-Lenvima combo aces confirmatory study in endometrial cancer
Merck breathes a sigh of relief as Keytruda-Lenvima combo aces confirmatory study in endometrial cancer
Endpoints
Merck
FDA
Keytruda
Eisai
Lenvima
clinical trials
endometrial cancer
Flag link:
Surface Oncology To Test SRF388 Plus Keytruda Combo In Solid Tumor Settings
Surface Oncology To Test SRF388 Plus Keytruda Combo In Solid Tumor Settings
Benzinga
Surface Oncology
Merck
Keytruda
SRF388
solid tumors
Flag link:
Merck follows Bristol's suit, pulling Keytruda's SCLC nod. Is the FDA's accelerated approval reckoning finally here?
Merck follows Bristol's suit, pulling Keytruda's SCLC nod. Is the FDA's accelerated approval reckoning finally here?
Fierce Pharma
Merck
Keytruda
FDA
small cell lung cancer
Opdivo
Bristol-Myers Squibb
Flag link:
Libtayo scores second OK in two weeks, this time for front-line NSCLC. Can it take on Keytruda?
Libtayo scores second OK in two weeks, this time for front-line NSCLC. Can it take on Keytruda?
Endpoints
Regeneron
Libtayo
non-small cell lung cancer
Merck
Keytruda
Flag link:
Did Merck Make a Mistake With a Key FDA Filing?
Did Merck Make a Mistake With a Key FDA Filing?
Motley Fool
Merck
Keytruda
FDA
triple negative breast cancer
Flag link:
Merck's Keytruda Plus Eisai's Lenvima Could Open New Standard of Care in Renal Cancer
Merck's Keytruda Plus Eisai's Lenvima Could Open New Standard of Care in Renal Cancer
BioSpace
Merck
ASCO GU
Keytruda
Eisai
Lenvima
renal cell carcinoma
Flag link:
Another Keytruda combo tops standard of care in advanced kidney cancer, posing new test for Bristol's I/O med
Another Keytruda combo tops standard of care in advanced kidney cancer, posing new test for Bristol's I/O med
Endpoints
Merck
advanced kidney cancer
Keytruda
Flag link:
FDA panel admonishes Merck with a gentle — and rare — slapdown for rushing its pitch on an accelerated OK for adjuvant Keytruda in TNBC
FDA panel admonishes Merck with a gentle — and rare — slapdown for rushing its pitch on an accelerated OK for adjuvant Keytruda in TNBC
Endpoints
Merck
FDA
Keytruda
Flag link:
FDA Action Alert: Adamas, Mallinckrodt and Merck
FDA Action Alert: Adamas, Mallinckrodt and Merck
BioSpace
FDA
Adamas Pharmaceuticals
Mallinckrodt
Merck
Gocovri
StrataGraft
Keytruda
triple negative breast cancer
Flag link:
Merck's Keytruda Proves Better Alone in Combination Trial With BMS' Yervoy
Merck's Keytruda Proves Better Alone in Combination Trial With BMS' Yervoy
BioSpace
Merck
Keytruda
Bristol-Myers Squibb
Yervoy
non-small cell lung cancer
Flag link:
WCLC: With Keytruda-Yervoy data, Merck casts doubt on Opdivo's place in lung cancer
WCLC: With Keytruda-Yervoy data, Merck casts doubt on Opdivo's place in lung cancer
Fierce Pharma
WCLC
Keytruda
Yervoy
Merck
Bristol-Myers Squibb
Flag link:
The year immuno-oncology could break into perioperative settings
The year immuno-oncology could break into perioperative settings
EP Vantage
Merck
Keytruda
breast cancer
immuno-oncology
perioperative breast cancer
Flag link:
GSK, German Merck's $4.2B bintrafusp alfa drug a bust, fails to beat king Keytruda in lung cancer
GSK, German Merck's $4.2B bintrafusp alfa drug a bust, fails to beat king Keytruda in lung cancer
Fierce Biotech
GSK
Merck KGaA
bintrafusp alfa
clinical trial
Merck
Keytruda
Flag link:
Merck, Bristol Myers, AstraZeneca and Roche lose bid to expand PD-1/L1 reach in China
Merck, Bristol Myers, AstraZeneca and Roche lose bid to expand PD-1/L1 reach in China
Fierce Pharma
Merck
Bristol-Myers Squibb
AstraZeneca
Roche
Keytruda
Opdivo
Imfinzi
Tecentriq
China
PD-1 inhibitors
Flag link:
FDA grants priority review to KEYTRUDA for treatment of esophageal and gastroesophageal junction cancer
FDA grants priority review to KEYTRUDA for treatment of esophageal and gastroesophageal junction cancer
Pharmaceutical Business Review
Merck
Keytruda
FDA
esophageal cancer
gastroesophageal cancer
Flag link:
Pages
1
2
3
4
5
6
7
8
9
…
next ›
last »